BRILIQUE® (ticagrelor)

BRILIQUE (ticagrelor) is the only P2Y12 inhibitor licensed in combination with aspirin to protect patients with prior MI and a high risk* of atherothrombotic events against subsequent CV events in both the acute and long-term treatment settings†1

*High risk is defined as ≥1 additional atherothrombotic risk factor (age ≥65 years, >1 prior MI, multivessel coronary artery disease, diabetes requiring medication, chronic non-end-stage renal dysfunction)1

BRILIQUE (ticagrelor) 90mg twice daily  in combination with  acetylsalicylic acid (ASA) is indicated for patients with Acute Coronary Syndromes (ACS) for up to 12 months. BRILIQUE (ticagrelor) 90mg twice daily is not indicated for use in patients beyond 12 months. There are limited data on the efficacy and safety of BRILIQUE (ticagrelor) 60mg beyond 3 years of extended treatment


Brilique Product Information

Prescribing BRILIQUE (ticagrelor) 90mg

BRILIQUE (ticagrelor) 90mg can be used in a wide range of ACS patients

BRILIQUE (ticagrelor) 90mg twice daily, co-administered with aspirin, is indicated for the prevention of atherothrombotic events in adult patients with ACS (unstable angina [UA], non ST-segment-elevated MI [NSTEMI] or ST-segment-elevation MI [STEMI]), including patients managed medically, and those who are managed with percutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG), for up to 12 months unless discontinuation is clinically indicated.1,6

BRILIQUE (ticagrelor) 90mg loading and maintenance dose

Treatment with BRILIQUE (ticagrelor) should be initiated with a single 180mg loading dose (two tablets of 90mg) and then continued at 90mg twice daily with concomitant ASA.1

The image shows the starting and maintenance dose for BRILIQUE 90mg for up to 12 months of treatment
The image shows the starting and maintenance dose for BRILIQUE 90mg for up to 12 months of treatment

Guidelines in the UK recommend a loading dose of ASA 300 mg in ASA naive patients

No dose adjustment is required across ACS patient populations including:1

Switching from clopidogrel to BRILIQUE (ticagrelor) 90mg

Patients can be switched from clopidogrel to BRILIQUE (ticagrelor) 90mg twice daily without interruption of antiplatelet effect1. If a switch is needed in the chronic setting the maintenance dose (90mg twice daily) should be commenced 24 hours following the last dose of the other antiplatelet medication. In the acute phase international guidelines e.g. ESC13, endorse giving a loading dose of ticagrelor (180 mg) before commencing the maintenance dose of 90 mg twice daily as usual.